Edition:
India

Sellas Life Sciences Group Inc (SLS.OQ)

SLS.OQ on NASDAQ Stock Exchange Capital Market

0.94USD
15 Aug 2018
Change (% chg)

$-0.14 (-12.94%)
Prev Close
$1.08
Open
$1.02
Day's High
$1.03
Day's Low
$0.92
Volume
84,242
Avg. Vol
73,340
52-wk High
$13.43
52-wk Low
$0.92

Latest Key Developments (Source: Significant Developments)

Sellas Life Sciences Q2 Loss Per Share $1.26
Wednesday, 15 Aug 2018 

Aug 15 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.26.AS OF JUNE 30, 2018, CASH AND CASH EQUIVALENTS WERE $1.3 MILLION.  Full Article

Sellas Life Sciences Group Files For Offering Of Up To 9.4 Mln Shares
Friday, 20 Jul 2018 

July 19 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO 9.4 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Empery Asset Management Lp Reports 9.99 pct Passive Stake In Sellas Life Sciences Group Inc As Of July 12
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Sellas Life Sciences Group Inc ::EMPERY ASSET MANAGEMENT, LP REPORTS 9.99 PERCENT PASSIVE STAKE IN SELLAS LIFE SCIENCES GROUP INC AS OF JULY 12, 2018 - SEC FILING.  Full Article

Sellas Life Sciences Says Offering Of 6.08 Mln Shares
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC SAYS OFFERING OF 6.08 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Galena Biopharma posts Q3 loss $0.15/shr from continuing operations
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Galena Biopharma Inc :Galena Biopharma reports third quarter 2017 financial results.Q3 loss per share $0.15 from continuing operations.Galena Biopharma Inc - ‍cash and cash equivalents of approximately $12.9 million as of September 30, 2017, compared with $18.1 million as of December 31, 2016​.  Full Article

Galena Biopharma says co and Cardinal Health entered into a settlement relating to product swap agreement​
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Galena Biopharma Inc :Galena Biopharma Inc says on October 12, co and Cardinal Health entered into a settlement relating to product swap agreement​ - SEC filing.Galena Biopharma Inc - ‍pursuant to agreement , co, Cardinal agreed to resolve all of their outstanding disputes over a product swap agreement​.Galena Biopharma Inc - ‍Cardinal will destroy all of zuplenz oral soluble film that is returned as a result of product swap agreement.Galena Biopharma Inc - ‍product swap agreement with Cardinal will be terminated as of effective date of agreement​.  Full Article

Galena Biopharma appoints Stephen Ghiglieri as CFO
Thursday, 3 Nov 2016 

Galena Biopharma Inc : Galena biopharma - Stephen Ghiglieri has been appointed as company's executive vice president and chief financial officer, effective immediately .Galena biopharma appoints Stephen F. Ghiglieri as executive vice president and chief financial officer.  Full Article

BRIEF-Galena Biopharma files registration statement related to previously-issued warrants (Sept. 30)
Tuesday, 4 Oct 2016 

Corrects headline and bullet to say company filed registration statement for shares upon exercise of previously-issued warrants for sale by selling stockholders not "files for secondary offering of up to 14 mln shares".issued warrants for sale by selling stockholders not "files for secondary offering of up to 14 mln shares") Sept 30 (Reuters) - Galena Biopharma Inc :Files registration statement for shares of common stock upon exercise of previously-issued warrants for sale by selling stockholders of up to 14 million shares.  Full Article

Galena Biopharma files for secondary offering of upto 14 mln shares - SEC filing
Saturday, 1 Oct 2016 

Galena Biopharma Inc :Galena Biopharma Inc files for secondary offering of upto 14 million shares of common stock - SEC filing.  Full Article

BRIEF-Sellas Life Sciences Files For Offering Of Up To $30 Mln

* SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO $30 MILLION - SEC FILING Source text: (https://bit.ly/2klt2uI) Further company coverage: